PRMT1 exhibits aberrant expression in liver cancer patient samples, where its levels are correlated with HCC progression, modulation of the tumor immune microenvironment, and dysregulation of fatty acid metabolism [145]. This evidence concerns the gene PRMT1 and liver cancer.